GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (STU:673) » Definitions » Price-to-Owner-Earnings

Cerevel Therapeutics Holdings (STU:673) Price-to-Owner-Earnings : (As of May. 26, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Cerevel Therapeutics Holdings Price-to-Owner-Earnings?

As of today (2024-05-26), Cerevel Therapeutics Holdings's share price is €38.20. Cerevel Therapeutics Holdings does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Cerevel Therapeutics Holdings's Price-to-Owner-Earnings or its related term are showing as below:


STU:673's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.37
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-26), Cerevel Therapeutics Holdings's share price is €38.20. Cerevel Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-2.52. Therefore, Cerevel Therapeutics Holdings's PE Ratio for today is At Loss.

As of today (2024-05-26), Cerevel Therapeutics Holdings's share price is €38.20. Cerevel Therapeutics Holdings's EPS without NRI for the trailing twelve months (TTM) ended in was €-2.52. Therefore, Cerevel Therapeutics Holdings's PE Ratio without NRI for today is At Loss.


Cerevel Therapeutics Holdings Price-to-Owner-Earnings Historical Data

The historical data trend for Cerevel Therapeutics Holdings's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerevel Therapeutics Holdings Price-to-Owner-Earnings Chart

Cerevel Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - - -

Cerevel Therapeutics Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cerevel Therapeutics Holdings's Price-to-Owner-Earnings

For the Biotechnology subindustry, Cerevel Therapeutics Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cerevel Therapeutics Holdings's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cerevel Therapeutics Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Cerevel Therapeutics Holdings's Price-to-Owner-Earnings falls into.



Cerevel Therapeutics Holdings Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Cerevel Therapeutics Holdings's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=38.20/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cerevel Therapeutics Holdings  (STU:673) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Cerevel Therapeutics Holdings Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Cerevel Therapeutics Holdings (STU:673) Business Description

Traded in Other Exchanges
Address
222 Jacobs Street, Suite 200, Cambridge, MA, USA, 02141
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Cerevel Therapeutics Holdings (STU:673) Headlines

No Headlines